Related Experiment Video
Updated: May 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Patients with oral anticoagulant therapy]
Argeme Serradilla Fernandez1, M Del Mar Reyero Hernandez, Blanca Guerrero Chacón
1argemesefe@hotmail.com
Introduction:
patients with ACO treatment must have some knowledge about the risks it causes. For this, that medical personnel must give and proper education in quality and quantity both the patient and the family.
Objectives:
determine the knowledge level in relation with the treatment ACO that the patients treated have in an AP query in a rural healthy area like is Plasencia.
Material And Method:
an observational descriptive retrospective study was conducted with 34 patients who was being treated with ACO. Data about pathologies, biometrics parameters about the clinical historical and interviews with the patients in the nurse query were picked up.
Results:
when the data were analyzed, the number of the patients according to the sex was equaled. Not according to the ages: people between 80-90 years old were the 26.5% from the total. About the pathologies causatives of the treatment, the FA is the most frequent with the 50%, followed by the pulmonary thromboembolism with the 23%. The control of the results was distributed controlling the youngest people at the hospital, the oldest people in AP. In relation with the tracing of the treatment, people with FA and valve prosthesis were the people most fulfilled.
Discussion:
To the medical personnel it is necessary to know the patient ACO profile, as the risk associated treatment. Young patients with cardiovascular pathologies are controlled at the hospital for they most variation in results, controlled in older primary care patients (AP) and rural residents have greater grip and better control. With this knowledge, medical personnel would make interventions for help adherence, monitoring control, treatment as well as the collaboration of family.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
